Total Payments
$90,597
2023 Payments
$393.70
Companies
8
Transactions
32
Medicare Patients
289
Medicare Billing
$42,936
Payment Breakdown by Category
Research$83,611 (92.3%)
Consulting$6,564 (7.2%)
Other$351.00 (0.4%)
Food & Beverage$71.24 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $83,611 | 24 | 92.3% |
| Consulting Fee | $6,564 | 3 | 7.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $351.00 | 1 | 0.4% |
| Food and Beverage | $71.24 | 4 | 0.1% |
Payments by Type
Research
$83,611
24 transactions
General
$6,986
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $35,862 | 9 | $0 (2023) |
| Janssen Research & Development, LLC | $33,328 | 14 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $14,447 | 3 | $0 (2018) |
| Avanir Pharmaceuticals, Inc. | $3,920 | 1 | $0 (2021) |
| Biogen, Inc. | $2,644 | 2 | $0 (2021) |
| Otsuka America Pharmaceutical, Inc. | $351.00 | 1 | $0 (2023) |
| Corium, LLC | $28.66 | 1 | $0 (2023) |
| AbbVie Inc. | $16.71 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $393.70 | 3 | Otsuka America Pharmaceutical, Inc. ($351.00) |
| 2021 | $6,581 | 4 | Avanir Pharmaceuticals, Inc. ($3,920) |
| 2018 | $17,296 | 7 | ACADIA Pharmaceuticals Inc ($15,981) |
| 2017 | $66,326 | 18 | Janssen Research & Development, LLC ($32,024) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/03/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $351.00 | General |
| Category: PSYCHIATRY | ||||||
| 04/03/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/20/2023 | Corium, LLC | Adlarity (Drug) | Food and Beverage | In-kind items and services | $28.66 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 08/11/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: NEUROSCIENCE | ||||||
| 06/11/2021 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 04/22/2021 | Biogen, Inc. | ADUHELM (Biological) | Consulting Fee | Cash or cash equivalent | $1,244.00 | General |
| Category: NEUROLOGY | ||||||
| 03/25/2021 | Avanir Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,920.00 | General |
| 07/16/2018 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $1,304.00 | Research |
| Study: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | ||||||
| 04/09/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,035.00 | Research |
| Study: ACP-103-042 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/02/2018 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $11.83 | General |
| 03/31/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: ACP-103-042 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/09/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $1,035.00 | Research |
| Study: ACP-103-042 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/08/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $2,210.63 | Research |
| Study: ACP-103-042 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/11/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $10,350.00 | Research |
| Study: ACP-103-042 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/22/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $210.00 | Research |
| Study: A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | ||||||
| 12/06/2017 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $4,820.63 | Research |
| Study: ACP-103-042 • Category: PDP | ||||||
| 11/09/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | BREXPIPRAZOLE (Drug) | — | Cash or cash equivalent | $276.60 | Research |
| Study: SAFETY FOLLOW-UP STUDY FOR SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE WHO PREVIOUSLY PARTICIPATED IN A DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE OR PLACEBO • Category: PSYCHIATRY | ||||||
| 11/08/2017 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $10,046.25 | Research |
| Study: ACP-103-042 • Category: PDP | ||||||
| 10/27/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $305.00 | Research |
| Study: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | ||||||
| 10/27/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $195.00 | Research |
| Study: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | ||||||
| 10/06/2017 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $5,000.00 | Research |
| Study: ACP-103-042 • Category: PDP | ||||||
| 10/06/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $981.65 | Research |
| Study: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | ||||||
| 10/05/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $2,287.00 | Research |
| Study: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | ||||||
| 09/07/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $6,201.00 | Research |
| Study: A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | ||||||
| 09/01/2017 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $1,838.00 | Research |
| Study: A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACP-103-042 | ACADIA Pharmaceuticals Inc | $35,848 | 8 |
| An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression | Janssen Research & Development, LLC | $20,015 | 9 |
| A STUDY OF THREE FIXED-DOSES OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $14,158 | 1 |
| A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | Janssen Research & Development, LLC | $13,313 | 5 |
| SAFETY FOLLOW-UP STUDY FOR SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE WHO PREVIOUSLY PARTICIPATED IN A DOUBLE-BLIND TRIAL OF BREXPIPRAZOLE OR PLACEBO | Otsuka Pharmaceutical Development & Commercialization, Inc. | $276.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 71 | 108 | $20,650 | $8,013 |
| 2022 | 3 | 68 | 166 | $27,010 | $10,812 |
| 2021 | 2 | 63 | 162 | $25,800 | $10,966 |
| 2020 | 4 | 87 | 198 | $30,550 | $13,147 |
Total Patients
289
Total Services
634
Medicare Billing
$42,936
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 18 | 46 | $7,770 | $3,521 | 45.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 16 | 16 | $5,760 | $2,091 | 36.3% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 23 | 29 | $4,060 | $1,261 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 17 | $3,060 | $1,139 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 61 | $10,950 | $5,339 | 48.8% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 27 | 68 | $9,520 | $3,351 | 35.2% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 17 | 37 | $6,540 | $2,121 | 32.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 78 | $14,040 | $6,776 | 48.3% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 34 | 84 | $11,760 | $4,189 | 35.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 25 | 67 | $12,060 | $5,183 | 43.0% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 32 | 80 | $11,080 | $4,387 | 39.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 14 | 27 | $3,240 | $2,101 | 64.8% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 16 | 24 | $4,170 | $1,476 | 35.4% |
About Dr. Cary Kohlenberg, MD
Dr. Cary Kohlenberg, MD is a Psychiatry healthcare provider based in Waukesha, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427134089.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cary Kohlenberg, MD has received a total of $90,597 in payments from pharmaceutical and medical device companies, with $393.70 received in 2023. These payments were reported across 32 transactions from 8 companies. The most common payment nature is "" ($83,611).
As a Medicare-enrolled provider, Kohlenberg has provided services to 289 Medicare beneficiaries, totaling 634 services with total Medicare billing of $42,936. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Waukesha, WI
- Active Since 10/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1427134089
Products in Payments
- NUPLAZID (Drug) $35,862
- BREXPIPRAZOLE (Drug) $14,435
- ADUHELM (Biological) $1,244
- REXULTI (Drug) $351.00
- Adlarity (Drug) $28.66
- VRAYLAR (Drug) $16.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Waukesha
Dr. James Rutherford, M.d, M.D
Psychiatry — Payments: $90,647
Psychiatry $90,647
David Holloway, M.d, M.D
Psychiatry — Payments: $13,587
Psychiatry $13,587
Gobind Kang-Chahal, Md, MD
Psychiatry — Payments: $1,534
Psychiatry $1,534
Dr. Rada Malinovic, Md, MD
Psychiatry — Payments: $1,355
Psychiatry $1,355
Randall Steinhaus, Md, MD
Psychiatry — Payments: $883.50
Psychiatry $883.50
Judith Kisicki, M.d, M.D
Psychiatry — Payments: $632.66
Psychiatry $632.66